Chosa Oncology (CHOSA) investor relations material

Presentation of new clinical data

• Platin-DRP® scores correlated with significant improvements in progression-free and overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy, with a hazard ratio of 0.602 for overall survival and 0.697 for progression-free survival.

• Median overall survival was 16.9 months for high Platin-DRP® score patients versus 5.5 months for low-score patients, indicating a clinically meaningful benefit.

• Platin-DRP is the first platform to predict response to platinum chemotherapy, addressing a major inefficiency in cancer treatment.

• No significant interaction was found between chemotherapy regimen (cisplatin vs. carboplatin) and DRP score, supporting the biomarker's applicability across both agents.

• Results are statistically significant and suggest a major improvement over current unguided platinum therapy.

Background and future directions

• Platin-DRP® is a 205-gene biomarker signature designed to predict benefit from cisplatin and carboplatin in cancer therapy, protected by a patent until 2038.

• Previous studies showed Platin-DRP® predicted benefit in adjuvant NSCLC and metastatic breast cancer, with high scores linked to improved survival.

• The tool may help guide platinum treatment selection in both clinical trials and practice, especially where no validated predictive biomarkers exist.

• Future research aims to assess Platin-DRP®'s predictive value in combination with PD-1/L1 inhibitors and platinum plus immunotherapy settings.

• CHOSA plans to pursue regulatory and commercial development, including partnerships and sublicensing.

Commercialization and market strategy

• Main users are oncologists for treatment planning and pharma companies for drug development.

• Revenue model includes out-licensing to diagnostic companies and pharma, with royalties or case-by-case deals.

• Target markets are balanced between the US, Europe, and China, with commercial upside per patient highest in the US.

• Potential to address 10% of the 1 million annual lung cancer patients treated with platinum, with a $1,000 test and 20% margin.

• Exploring partnerships with both global pharma and regional diagnostic companies, with flexibility for trade sale or licensing.